within Pharmacolibrary.Drugs.ATC.G;

model G03AA16
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.91,
    Cl             = 5.833333333333333e-05,
    adminDuration  = 600,
    adminMass      = 2 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.05,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>G03AA16</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>A fixed-dose combination oral contraceptive containing dienogest (a progestin) and ethinylestradiol (an estrogen). It is used for contraception and management of acne vulgaris in women desiring oral contraception. The combination is approved and widely used globally.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters for healthy female volunteers of reproductive age following steady-state administration of 2 mg dienogest and 0.03 mg ethinylestradiol orally once daily.</p><h4>References</h4><ol><li><p>Pérez-Campos, EF (2010). Ethinylestradiol/dienogest in oral contraception. <i>Drugs</i> 70(6) 681–689. DOI:<a href=&quot;https://doi.org/10.2165/11536320-000000000-00000&quot;>10.2165/11536320-000000000-00000</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/20394455/&quot;>https://pubmed.ncbi.nlm.nih.gov/20394455</a></p></li><li><p>Stanczyk, FZ, et al., &amp; Archer, DF (2024). Comparison of estrogenic components used for hormonal contraception. <i>Contraception</i> 130 110310–None. DOI:<a href=&quot;https://doi.org/10.1016/j.contraception.2023.110310&quot;>10.1016/j.contraception.2023.110310</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/37863464/&quot;>https://pubmed.ncbi.nlm.nih.gov/37863464</a></p></li><li><p>Wiesinger, H, et al., &amp; Friedrich, C (2020). The Effects of Weak and Strong CYP3A Induction by Rifampicin on the Pharmacokinetics of Five Progestins and Ethinylestradiol Compared to Midazolam. <i>Clinical pharmacology and therapeutics</i> 108(4) 798–807. DOI:<a href=&quot;https://doi.org/10.1002/cpt.1848&quot;>10.1002/cpt.1848</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32275771/&quot;>https://pubmed.ncbi.nlm.nih.gov/32275771</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end G03AA16;
